title: BCL6 is a negative prognostic factor and exhibits pro-oncogenic activity in ovarian cancer.
abstract: BACKGROUND
  Dysregulation of BCL6 plays critical oncogenic roles and facilitates tumorigenesis in various malignancies. However, whether the aberrant expression of BCL6 in ovarian carcinoma is associated with malignancy, metastasis or prognosis remains unknown. Our study aimed to investigate the expression of BCL6 in ovarian carcinoma and its possible correlation with clinicopathological features as well as patient survival to reveal its biological effects in ovarian tumor progression.
  
  
  METHODS
  Immunochemistry analysis was performed in 105 cases of ovarian carcinoma covering the histological types of serous, endometrioid and clear cell. Spearman analysis was used to calculate the correlation between pathological parameters and the expression of BCL6. Kaplan-Meier method and Cox proportional hazards analysis were used to analyze the disease-specific survival (DSS) and disease-free survival (DFS). We also assessed whether overexpression and knockdown of BCL6 influence in vitro cell proliferation, cell cycle progression, as well as tumor cell invasion and migration.
  
  
  RESULTS
  The expression of BCL6 was higher in all three major kinds of ovarian cancer in comparison with paratumorous epithelium. BCL6 expression was tightly correlated with FIGO staging, lymph node metastasis and recurrence. Higher expression of BCL6 led to a significantly poorer DSS and DFS and multivariate analysis revealed that BCL6 was an independent risk factor of DSS and DFS. Enforced overexpression of BCL6 in ovarian tumor cells stimulated proliferation by inducing G1-S transition, and promoted tumor cell invasion and migration. Conversely, RNA interference-mediated silencing BCL6 expression inhibited proliferation by altered cell cycle progression and reduced the ability of the cells to migrate, and invade the extracellular matrix in culture.
  
  
  CONCLUSIONS
  Our study suggests that the inappropriate activation of BCL6 predicts poor prognosis and promotes tumor progression in ovarian carcinoma. Targeting BCL6 could be a novel therapeutic choice for treating ovarian carcinoma patients.
authors: Department of Pathology, Fudan University Shanghai Cancer Center Shanghai, 200032, China ; Department of Oncology, Fudan University Shanghai Cancer Center Shanghai, 200032, China ; Institute of Pathology, Fudan University Shanghai 200032, China ; Institute of Biomedical Sciences, Fudan University Shanghai, 200032, China ; Department of Pathology, Obstetrics and Gynecology Hospital of Fudan University Shanghai, 200032, China ; Department of Pathology, Shanghai Medical College, Fudan University Shanghai, 200032, China.
authors: Yi-Qin
authors: YQ
authors: Wang
authors: Department of Pathology, Fudan University Shanghai Cancer Center Shanghai, 200032, China ; Department of Oncology, Fudan University Shanghai Cancer Center Shanghai, 200032, China ; Institute of Pathology, Fudan University Shanghai 200032, China ; Institute of Biomedical Sciences, Fudan University Shanghai, 200032, China.
authors: Mi-Die
authors: MD
authors: Xu
authors: Department of Pathology, Fudan University Shanghai Cancer Center Shanghai, 200032, China ; Department of Oncology, Fudan University Shanghai Cancer Center Shanghai, 200032, China ; Institute of Pathology, Fudan University Shanghai 200032, China ; Institute of Biomedical Sciences, Fudan University Shanghai, 200032, China.
authors: Wei-Wei
authors: WW
authors: Weng
authors: Department of Pathology, Fudan University Shanghai Cancer Center Shanghai, 200032, China ; Department of Oncology, Fudan University Shanghai Cancer Center Shanghai, 200032, China ; Institute of Pathology, Fudan University Shanghai 200032, China ; Institute of Biomedical Sciences, Fudan University Shanghai, 200032, China.
authors: Ping
authors: P
authors: Wei
authors: Department of Pathology, Fudan University Shanghai Cancer Center Shanghai, 200032, China ; Department of Oncology, Fudan University Shanghai Cancer Center Shanghai, 200032, China ; Institute of Pathology, Fudan University Shanghai 200032, China ; Institute of Biomedical Sciences, Fudan University Shanghai, 200032, China.
authors: Yu-Si
authors: YS
authors: Yang
authors: Department of Pathology, Fudan University Shanghai Cancer Center Shanghai, 200032, China ; Department of Oncology, Fudan University Shanghai Cancer Center Shanghai, 200032, China ; Institute of Pathology, Fudan University Shanghai 200032, China ; Institute of Biomedical Sciences, Fudan University Shanghai, 200032, China.
authors: Xiang
authors: X
authors: Du
keywords: BCL6; invasion; ovarian carcinoma; prognosis; proliferation
references: Nature. 2004 Dec 2;432(7017):635-9
references: 15577913
references: Blood. 1994 Apr 1;83(7):1757-9
references: 8142643
references: EMBO J. 1995 Dec 15;14(24):6209-17
references: 8557040
references: Blood. 2013 Mar 21;121(12 ):2165-6
references: 23520325
references: J Transl Med. 2013 Jun 20;11:151
references: 23787019
references: Tumour Biol. 2014 Sep;35(9):9053-9
references: 24913705
references: Oncol Rep. 2014 Jun;31(6):2660-8
references: 24715097
references: Int J Cancer. 2009 Aug 15;125(4):977-81
references: 19405121
references: Int J Mol Med. 2014 Jun;33(6):1514-22
references: 24676803
references: Curr Cancer Drug Targets. 2013 Nov;13(9):963-72
references: 24168186
references: J Cell Biochem. 2011 Sep;112(9):2508-17
references: 21557297
references: Blood. 2009 May 28;113(22):5536-48
references: 19307668
references: Med J Aust. 2014 Sep 1;201(5):283-8
references: 25163381
references: Br J Cancer. 2009 Apr 21;100(8):1320-9
references: 19337254
references: Oncogene. 2014 Apr 24;33(17 ):2215-24
references: 23708665
references: BMC Cancer. 2014 Jun 10;14:418
references: 24917186
references: Oncogene. 2015 Feb 26;34(9):1073-82
references: 24662818
references: Arch Gynecol Obstet. 2014 Nov;290(5):839-42
references: 25082067
references: Akush Ginekol (Sofiia). 2013;52(4):10-2
references: 24283071
references: PLoS One. 2013;8(3):e57692
references: 23520479
references: Cancer Cell. 2010 Apr 13;17(4):400-11
references: 20385364
references: Carcinogenesis. 2008 Dec;29(12):2243-51
references: 18713838
references: Nat Commun. 2014 Jun 02;5:3904
references: 24887457
references: Oncotarget. 2013 Jul;4(7):1093-102
references: 23852366
references: PLoS One. 2014 Mar 17;9(3):e92254
references: 24638100
references: Adv Immunol. 2010;105:193-210
references: 20510734
references: Cancer Res. 2010 Feb 15;70(4):1711-21
references: 20124477